Sugi Predict

Sugi Predict / Compounds / SCHEMBL712856

SCHEMBL712856

SCHEMBL712856

O=C(NCCCCCCO)C(F)(F)F

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.83
▸ KMT2A Q03164 1/20 0.83
▸ ALDH1A1 P00352 3/20 0.78
▸ SMN1; SMN2 Q16637 3/20 0.78
▸ POLB P06746 1/20 0.78
▸ EPHX1 P07099 2/20 0.68
▸ CA2 P00918 4/20 0.67
▸ CA12 O43570 3/20 0.67
▸ CA9 Q16790 3/20 0.67
▸ CA3 P07451 2/20 0.67
▸ CA5A P35218 2/20 0.67
▸ CA5B Q9Y2D0 2/20 0.67
▸ CA14 Q9ULX7 2/20 0.67
▸ CA4 P22748 1/20 0.67
▸ CA6 P23280 1/20 0.67
▸ CA7 P43166 1/20 0.67
▸ TDP1 Q9NUW8 1/20 0.48
▸ CA1 P00915 3/20 0.42
▸ GLA P06280 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221326 1.00 MEN1 (0.83) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL2994990 1.00 MEN1 (0.83) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL3215133 1.00 MEN1 (0.83) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL16210325 1.00 MEN1 (0.83) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL864398 0.98 ALDH1A1 (0.82) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL865618 0.91 ALDH1A1 (0.77) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL29982917 0.91 MEN1 (1.00) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL27056159 0.89 MEN1 (0.66) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL27889238 0.89 ALDH1A1 (1.00) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL570465 0.84 CA3 (0.91) MEN1KMT2AALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118165059-A Synthesis method of N2-C6 amino modified deoxyguanosine monomer 生工生物工程（上海）股份有限公司 2024-06-11 — — CN claimed
CN-109817396-B Hard composite insulator and preparation method thereof 河北荣森电气有限公司 2020-05-26 — — CN claimed
US-7531524-B2 Modulators of coagulation factors with enhanced stability REGADO BIOSCIENCES, INC. (US) 2009-05-12 — — US claimed
US-20080125383-A1 For host undergoing surgery or coronary artery bypass TOBIRA THERAPEUTICS, INC. 2008-05-29 — — US claimed
US-20070105809-A1 Modulators of coagulation factors with enhanced stability REGADO BIOSCIENCES, INC. 2007-05-10 — — US claimed
EP-0291982-A2 Cyclic anticoagulant peptides MERRELL DOW PHARMACEUTICALS INC. (US) 1988-11-23 — — EP claimed
EP-4572795-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS The University of Chicago (US) 2025-06-25 — — EP disclosed
US-20250122502-A1 Bifunctional Molecules and Methods of Using Thereof FLAGSHIP PIONEERING, INC. (US) 2025-04-17 — — US disclosed
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION THE JOHNS HOPKINS UNVERSITY 2025-04-10 — — US disclosed
US-20240400684-A1 ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-12-05 — — US disclosed
CN-118165059-A Synthesis method of N2-C6 amino modified deoxyguanosine monomer 生工生物工程（上海）股份有限公司 2024-06-11 — — CN disclosed
WO-2024040169-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS THE UNIVERSITY OF CHICAGO (US) 2024-02-22 — — WO disclosed
US-20240052353-A1 Bispecific Aptamer Compositions for the Treatment of Retinal Disorders Drive Therapeutics, L.L.C. (US) 2024-02-15 — — US disclosed
US-4833251-A FLUORESCENT COMPOUNDS SISKA DIAGNOSTICS, INC. (US) 1989-05-23 — — US disclosed
EP-0292128-A1 Improved DNA probes TAMIR BIOTECHNOLOGY LTD (IL) 1988-11-23 — — EP disclosed
EP-0119448-B1 OLIGONUCLEOTIDE DERIVATIVES AND PRODUCTION THEREOF WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1987-04-29 — — EP disclosed
EP-0209996-A2 Nucleic acid probes comprising N4 -(substituted amino)cytidines SISKA DIAGNOSTICS,INC. (US) 1987-01-28 — — EP disclosed
US-4336369-A Selectively protected 1-N-(ω-aminoalkoxycarbonyl)-sisomicin derivatives BAYER AKTIENGESELLSCHAFT (DE) 1982-06-22 — — US disclosed
US-4312859-A ANTIBIOTICS, BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1982-01-26 — — US disclosed
EP-0019843-A1 Sisomicin derivatives, process for their preparation and their use as medicines BAYER AG (DE) 1980-12-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240052353-A1 Bispecific Aptamer Compositions for the Treatment of Retinal Disorders KDR, TIE1, TEK MEN1 2183/4885KMT2A 1889/4885ALDH1A1 3482/4885
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION OPRM1, OPRK1, OPRL1 MEN1 4823/4885KMT2A 2167/4885ALDH1A1 2483/4885
US-20080125383-A1 For host undergoing surgery or coronary artery bypass NSUN2, SERPINC1, NSUN3 MEN1 3551/4885KMT2A 2465/4885ALDH1A1 4034/4885
US-20070105809-A1 Modulators of coagulation factors with enhanced stability SERPINC1, TFPI, F13B MEN1 3184/4885KMT2A 2169/4885ALDH1A1 3826/4885
US-20250122502-A1 Bifunctional Molecules and Methods of Using Thereof EFTUD2, DDX21, SNRPE MEN1 3415/4885KMT2A 3085/4885ALDH1A1 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.